-
-
7 . Periodical
Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD)
- 저자
- by Heeney, Matthew M.; Rees, David C.; De Montalembert, Mariane; Odame, Isaac; Brown, R. Clark Clark, et al.
- 소스
- Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p12-12, 1p
-
7 . Periodical
Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study
- 저자
- by Kalfa, Theodosia A.; Telen, Marilyn J.; Saraf, Santosh L.; Brown, R. Clark Clark; Giger Seu, Katie, et al.
- 소스
- Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p8-8, 1p
-
7 . Periodical
Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks
- 저자
- by Brown, R. Clark Clark; Saraf, Santosh L.; Cruz, Kimberly; Idowu, Modupe; Kalfa, Theodosia A., et al.
- 소스
- Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p9-9, 1p
-
-
7 . Periodical
GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers
- 저자
- by Brown, R. Clark Clark; Redfern, Andrew; Lisbon, Eleanor; Washington, Carla; Agodoa, Irene, et al.
- 소스
- Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p3099-3099, 1p